Patent · US Active

Identification of tumor-associated cell surface antigens for diagnosis and therapy

US9267177B2 · kind B2 · utility

6Cited by

0References

7Claims

0Family size

Assignee

BioNTech AG · DE

Inventors

Ozlem Tureci · Homburg, DE
Ugur Sahin · Mainz, DE
Gerd Helftenbein · Mücke, DE
Volker Schlüter · Schwanau, DE

Key dates

Filing date	Aug 19, 2015
Grant date	Feb 23, 2016
Priority date	—
Expiry date	Aug 19, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/56
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.